1-[(4-Fluorophenyl)methyl]cyclobutyl-methanamine | 1439896-37-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(4-Fluorophenyl)methyl]cyclobutyl-methanamine
• 英文别名: [1-[(4-fluorophenyl)methyl]cyclobutyl]methanamine
• CAS: 1439896-37-3
• 化学式: C₁₂H₁₆FN
• 分子量: 193.26
• InChiKey: QOKZPOFWIQOHQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[(4-Fluorophenyl)methyl]cyclobutyl-methanamine 、 6-氧代-1,6-二氢吡嗪-2-羧酸 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以9.19 %的产率得到N-([1-[(4-fluorophenyl)methyl]cyclobutyl]methyl)-6-hydroxypyrazine-2-carboxamide hydrochloride
  参考文献：
  名称：

  INHIBITORS OF MPTP

  摘要：

  The invention relates to compounds of formula (I), and related aspects.

  公开号：

  WO2024153946A1

文献信息

• Novel Bicyclic Pyridinones
  申请人：Pfizer Inc.

  公开号：US20140088111A1

  公开（公告）日：2014-03-27

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受盐已被披露，其中所述化合物具有规范中定义的Formula I结构。相应的药用组合物、治疗方法、合成方法和中间体也已被披露。
• [EN] NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS<br/>[FR] NOUVELLES PYRIDINONES BICYCLIQUES UTILISÉES COMME MODULATEURS DE GAMMA-SÉCRÉTASE
  申请人：PFIZER

  公开号：WO2015049616A1

  公开（公告）日：2015-04-09

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受的盐已被披露，其中这些化合物具有规范中定义的 Formula I 的结构。相应的药物组合物、治疗方法、合成方法和中间体也已被披露。
• Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders
  申请人：Pfizer Inc.

  公开号：US20150072990A1

  公开（公告）日：2015-03-12

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药学上可接受的盐，其中化合物的结构如规格中定义的公式I。同时还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS
  申请人：PFIZER INC.

  公开号：US20160229847A1

  公开（公告）日：2016-08-11

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula II as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药学上可接受的盐，其中该化合物具有规定在规范中的II式结构。还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders
  申请人：Pfizer Inc.

  公开号：US20160024088A1

  公开（公告）日：2016-01-28

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本文披露了化合物及其药学上可接受的盐，其中该化合物的结构如规范中定义的I式。同时还披露了相应的药物组合物、治疗方法、合成方法和中间体。